SI-BONE, Inc.
SI-BONE, Inc. develops and commercializes implant systems and surgical instruments for sacropelvic conditions, with a core focus on minimally invasive treatment of sacroiliac joint dysfunction and degeneration. The company is based in the United States and sells through direct and partner sales channels in the U.S. and selected international markets, including Europe.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueMinimally invasive implants and instruments used to treat sacroiliac joint dysfunction and degeneration.
Implant systems designed for adult spinal deformity and thoracolumbar stabilization procedures.
Implants and tools used in pelvic fracture fixation and trauma-related procedures.
Adjunct bone products, instruments, and procedure support items used with the implant portfolio.
Customers
SI-BONE sells primarily to surgeons and hospitals that perform minimally invasive sacropelvic and spine procedures. Its products are used by orthopedic surgeons, spine surgeons, and other physicians treating sacroiliac joint disease, adult spinal deformity, and pelvic trauma. Purchasing decisions are influenced by clinical evidence, ease of use, training support, reimbursement coverage, and procedure outcomes.
Buy implant systems and instruments for sacroiliac fusion, spinal fixation, and pelvic trauma procedures because they need clinically supported, anatomy-specific solutions.
Purchase or consignment-use trays, implants, and procedure support items to enable cases and maintain inventory availability.
Influence adoption through reimbursement coverage and payment policies that affect procedure economics.
Buy or distribute products in non-U.S. markets where SI-BONE uses a mixed direct and partner model.
Strategy
SI-BONE’s strategy centers on expanding procedure volume by broadening its product portfolio and increasing the number of active physicians using its systems. The company is also focused on improving sales-force productivity, deploying instrument trays more efficiently, and tightening supply-chain and manufacturing execution to support growth. These priorities reinforce its position in anatomy-specific, minimally invasive sacropelvic surgery.
More indications and product lines increase the number of cases a surgeon can treat with SI-BONE systems.
Higher sales-force efficiency supports broader physician coverage without proportional overhead growth.
Reliable implant availability and lower rework are important in procedure-driven medical device sales.
Geography
Q1/2026The United States is the company’s core market and accounted for 95% of revenue in 2025, with international markets contributing the remaining 5%. International activity is concentrated in Europe and other selected markets where SI-BONE uses direct sales, agents, and resellers. Geography matters because the business depends on U.S. reimbursement, while international growth requires regulatory clearances and local commercial coverage.
Share of the revenue the company reports by geography.
Risks
SI-BONE faces competition from other implant and spine companies, and adoption depends on clinical evidence, reimbursement, and surgeon preference. The business is also exposed to supply-chain disruptions, sterilization dependencies, regulatory scrutiny around physician relationships, and cybersecurity risks tied to sensitive data and connected systems.
- Intense competition in sacropelvic and spine implantsImpact: HighLikelihood: Medium
Surgeons can choose alternative products based on evidence, ease of use, and reimbursement.
Exposure: Core U.S. implant franchise
- Supply-chain and sterilization disruptionsImpact: HighLikelihood: Medium
The company relies on third-party suppliers for materials, components, and sterilization services.
Exposure: Product availability and case fulfillment
- Regulatory scrutiny of physician financial relationshipsImpact: HighLikelihood: Low
Consulting, royalty, and co-marketing arrangements may be challenged under anti-kickback laws.
Exposure: Commercial relationships and compliance
- Sales-force retention and productivity riskImpact: MediumLikelihood: Medium
The model depends on trained reps and agents who support surgeons and case coverage.
Exposure: Commercial execution
- Cybersecurity and data privacy incidentsImpact: MediumLikelihood: Low
A breach could expose confidential information, disrupt systems, and create legal liability.
Exposure: IT systems and sensitive data
Accounting
Judgemental itemsProcedure-driven sales and consignment arrangements can affect when revenue is recorded.
Impact: Quarterly revenue timing and comparability
The company has historically experienced lower summer sales and stronger fourth-quarter sales.
Impact: Quarterly trend interpretation
Tray deployment and inventory levels affect asset utilization and balance-sheet carrying values.
Impact: Working capital and gross margin
Management uses estimates for assets, liabilities, and expenses under U.S. GAAP.
Impact: Reported earnings and balance-sheet values
Similar listed companies
Publicly listed companies with a comparable business focus.
Tenon Medical, Inc.
TNONW · Surgical & Medical Instruments & Apparatus
Globus Medical, Inc
GMED · Surgical & Medical Instruments & Apparatus
Globus Medical is a U.S.-based medical device company focused on musculoskeletal care, with products used in spine, orthopedic trauma, hip, knee, extremity and neurosurgical procedures.
Bioventus Inc.
BVS · Surgical & Medical Instruments & Apparatus
Treace Medical Concepts, Inc
TMCI · Surgical & Medical Instruments & Apparatus
Treace Medical Concepts is a U.S.-based medical device company focused on surgical systems for bunion and midfoot correction.
Intuitive Surgical, Inc
ISRG · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Intuitive Surgical designs and sells robotic-assisted surgical systems and related instruments, accessories, software, and services used to perform minimally invasive procedures.
Orthofix Medical Inc.
OFIX · Surgical & Medical Instruments & Apparatus
Last updated: 24/09/2026